Key facts
- This page summarizes Dean J. Mitchell's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 May 2024, 18:09.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.